Besieged Biogen to lay off 650, sell assets
Biotech firm is also boosting its budget to pursue new deals
After six months during which Biogen Idec Inc.'s key drug was withdrawn from the market, its stock price plummeted, and federal regulators investigated allegations of insider trading, the company yesterday said it would lay off 650 of its 4,000 employees and sell assets to cut costs. (Full article: 782 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
